A systems biology approach to RESOLVE the molecular pathology of the hallmarks of patients with metabolic syndrome and its co-morbidities; Hypertriglyceridemia, low HDL-cholesterol and loss of glycemic control.

A systems biology approach to RESOLVE the molecular pathology of the hallmarks of patients with metabolic syndrome and its co-morbidities; Hypertriglyceridemia, low HDL-cholesterol and loss of glycemic control. - Resolve-study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41556

Enrollment

Registered

2013-11-22

Start date

2014-08-26

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome

Interventions

Roux-en Y gastric bypass

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Scheduled for bariatric surgery - 18-65 years of age - Ability to provide informed consent - Stable weight 3 months prior to inclusion - Willingness to stop lipid lowering and antiacid (PPI) medication 4 weeks prior to study measurements.

Exclusion criteria

Exclusion criteria: - Primary lipid disorder - Childhood onset obesity (i.e. 150/95 mmHg) - Renal insufficiency (creatinin > 150 umol/L) - Excessive alcohol intake (> 14 units/week) - Pregnancy, females who are breastfeeding - Contraindication to MR scanning (i.e. pacemaker, metallic foreign body, claustrophobia)

Design outcomes

Primary

Measure	Time frame
Differences in tissue expression of genes involved in glucose and lipid metabolism in relation to metabolic fluxes between obese subtypes and between men and women, and the characteristics of the metabolic changes patients undergo during 1 year of extreme weight loss following bariatric surgery.	—

Secondary

Measure	Time frame
- Differences in parasympathetic/sympathetic balance and energy expenditure - Differences in liver fat in relation to liver gene expression profiles and metabolic fluxes. - Differences in gut microbiota composition in relation to metabolic fluxes. - The effects of fructose in De Novo Lipogenesis and its relation to other metabolic fluxes.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)